Tirzepatide 10mg

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that has generated significant interest in the metabolic research community. This innovative compound activates both incretin pathways simultaneously, enabling researchers to investigate synergistic effects that cannot be studied with single-receptor agonists alone. Laboratory studies indicate that Tirzepatide's dual mechanism produces enhanced effects on glucose-dependent insulin secretion, lipid metabolism, and energy balance regulation compared to GLP-1 mono-agonists. The compound is particularly valuable for research into receptor crosstalk and comparative efficacy studies. Research Applications Dual incretin receptor research Glucose homeostasis studies Lipid metabolism investigations Comparative agonist studies Metabolic pathway research Intended for in vitro and in vivo research applications only.

FDA-approved for: - Type 2 diabetes (Mounjaro) - Obesity (Zepbound) - NASH research - Cardiovascular outcomes - Sleep apnea studies - PCOS management - Metabolic syndrome - Renal protection studies

Dual GIP/GLP-1 receptor agonist: 1. GLP-1 receptor activation 2. GIP receptor activation (unique) 3. Enhanced insulin secretion 4. Glucagon suppression 5. Delayed gastric emptying 6. Central appetite regulation 7. Improved insulin sensitivity

Superior weight loss (up to 22.5%) Excellent glycemic control Improved insulin sensitivity Cardiovascular benefits Liver fat reduction Better lipid profiles Blood pressure reduction Potential β-cell preservation

FDA-approved dosing: - Starting: 2.5mg weekly for 4 weeks - Titration: Increase by 2.5mg every 4 weeks - Maintenance: 5mg, 10mg, or 15mg weekly - Maximum: 15mg weekly - Same day each week

Common side effects: - Gastrointestinal (nausea, diarrhea) - Decreased appetite - Vomiting - Constipation - Injection site reactions - Fatigue - Rare: pancreatitis, gallbladder - Hypoglycemia (with insulin)